The effectiveness of the SGLT2 inhibitor sotagliflozin in worsening HF (wHF) was the subject of “The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure” (SOLOIST-WHF) trial. This evidence concerns the gene SLC5A2 and hydrops fetalis.